Huajin Capital

Huajin Capital (华金资本) is an investment fund active in China's venture capital market, with a visible concentration in healthcare and deep-tech. It has appeared as a repeat backer in biopharma deals: it co-led the Series A of CoreVision Biopharma (Bivision Pharmaceuticals) in July 2024 alongside Huajin Avenue , and joined rounds for nucleic-acid drug developer Onto Innovation and laser-chip company Angtuo in 2024 . It also holds positions in hard-tech names including semiconductor firm Zenitar, where it participated in a nearly RMB 600 million Series C in early 2026 as a continuing shareholder , and Tianjin Nankai Hecheng Technology, a materials-science company that closed a RMB 200 million Series B at end-2024 . The fund's activity spans both early and growth stages, often investing alongside established peers such as 5Y Capital, Qiming Venture Partners, and BlueRun Ventures.